Rocket Pharmaceuticals (RCKT) Stock Price, News & Analysis

Company Overview

Rocket Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing gene therapies for rare inherited diseases. The company leverages a lentiviral vector platform to design and deliver corrective genes to patients suffering from serious genetic disorders. Its research pipeline includes multiple ex vivo autologous gene therapy candidates aimed at addressing conditions such as Fanconi anemia, leukocyte adhesion deficiency-I, pyruvate kinase deficiency and Danon disease, among others.

Rocket’s proprietary platform is built on decades of lentiviral vector research and has been optimized to ensure stable gene transfer, durable expression and a favorable safety profile. The company’s lead programs are advancing through preclinical development and early-phase clinical trials, with a focus on demonstrating proof of concept for long-term therapeutic benefit. In addition to its internal pipeline, Rocket collaborates with academic institutions and patient advocacy groups to support translational research and broaden access to its treatments.

Founded in 2015 and headquartered in New York City, Rocket Pharmaceuticals operates research and manufacturing facilities in the United States and Europe. The company has established partnerships with contract research organizations and clinical sites across North America and the European Union to conduct multicenter trials. This global infrastructure positions Rocket to accelerate patient enrollment and streamline regulatory filings in multiple regions.

Under the leadership of Chairman and Chief Executive Officer Jason L. Cole, M.D., Rocket Pharmaceuticals is guided by a team of experienced executives, scientists and advisors. The company’s board includes experts in gene therapy, hematology and rare disease drug development, reflecting its commitment to advancing innovative treatments. Rocket continues to pursue strategic collaborations and funding opportunities to support the development of its pipeline and bring transformative therapies to patients with high unmet medical needs.

Key Stats

• Today's Range: $2.95 to $3.14
• 50-Day Range: $2.33 to $7.85
• 52-Week Range: $2.19 to $26.98
• Volume: 1.70 million shs
• Average Volume: 2.25 million shs
• Market Capitalization: $316.10 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $18.60
• Consensus Rating: Hold

Rocket Pharmaceuticals Stock Analysis - MarketRank™

Rocket Pharmaceuticals scored higher than 97% of companies evaluated by MarketBeat, and ranked 48th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Hold

Consensus Rating

Rocket Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.41, and is based on 8 buy ratings, 8 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Rocket Pharmaceuticals has been the subject of 17 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Rocket Pharmaceuticals are expected to grow in the coming year, from ($2.83) to ($2.22) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Rocket Pharmaceuticals is -1.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Rocket Pharmaceuticals is -1.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Rocket Pharmaceuticals has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

16.90% of the float of Rocket Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Rocket Pharmaceuticals has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Rocket Pharmaceuticals has recently decreased by 3.28%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Rocket Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Rocket Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.81

Percentage of Shares Shorted

16.90% of the float of Rocket Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Rocket Pharmaceuticals has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Rocket Pharmaceuticals has recently decreased by 3.28%, indicating that investor sentiment is improving.

News and Social Media

• Score: 1.8 / 5
• News Sentiment: 0.16

News Sentiment

Rocket Pharmaceuticals has a news sentiment score of 0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 40 news articles for Rocket Pharmaceuticals this week, compared to 9 articles on an average week.

Search Interest

Only 17 people have searched for RCKT on MarketBeat in the last 30 days. This is a decrease of -23% compared to the previous 30 days.

MarketBeat Follows

Only 7 people have added Rocket Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -22% compared to the previous 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Rocket Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,395.00 in company stock.

Percentage Held by Insiders

24.76% of the stock of Rocket Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

98.39% of the stock of Rocket Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

RCKT Stock Analysis - Frequently Asked Questions

How have RCKT shares performed this year?

Rocket Pharmaceuticals' stock was trading at $12.57 at the start of the year. Since then, RCKT shares have decreased by 76.5% and is now trading at $2.96.

How were Rocket Pharmaceuticals' earnings last quarter?

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) announced its quarterly earnings data on Tuesday, May, 13th. The biotechnology company reported ($0.56) earnings per share for the quarter, beating analysts' consensus estimates of ($0.58) by $0.02.

Who are Rocket Pharmaceuticals' major shareholders?

Rocket Pharmaceuticals' top institutional shareholders include Sovran Advisors LLC (0.18%) and Farther Finance Advisors LLC (0.01%). Insiders that own company stock include Rtw Investments, Lp, Gaurav Shah, Gotham Makker, Aaron Ondrey, David P Southwell, David P Southwell, Jonathan David Schwartz, Mark Andrew White, John Militello, Martin Wilson and Kinnari Patel.
View institutional ownership trends.

How do I buy shares of Rocket Pharmaceuticals?

Shares of RCKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Rocket Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Rocket Pharmaceuticals investors own include Voyager Therapeutics (VYGR), American Water Works (AWK), Marinus Pharmaceuticals (MRNS), Waste Connections (WCN), Humana (HUM), AU Optronics (AUOTY) and DiamondRock Hospitality (DRH).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 7/13/2025
• Next Earnings (Estimated): 8/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:RCKT
• CIK: 1281895
• Web: www.rocketpharma.com
• Phone: (609) 659-8001
• Fax: 646-224-9585
• Employees: 240
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Rocket Pharmaceuticals: $18.60
• High Price Target: $44.00
• Low Price Target: $5.00
• Potential Upside/Downside: +528.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.41
• Research Coverage: 17 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.63)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$258.75 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -64.92%
• Return on Assets: -56.13%

Debt

• Debt-to-Equity Ratio: 0.05
• Current Ratio: 9.19
• Quick Ratio: 9.19

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.08 per share
• Price / Book: 0.58

Miscellaneous

• Outstanding Shares: 106,790,000
• Free Float: 80,346,000
• Market Cap: $316.10 million
• Optionable: Optionable
• Beta: 0.67